Atom Therapeutics Announces First Patient Dosed in China Phase 3 Clinical Trial of Lingdolinurad (ABP-671) for Chronic Gout
Atom Therapeutics, an innovative biotechnology company focused on the discovery and development of novel therapies for metabolic, inflammatory, and cardiovascular diseases, today announced the initiation of its Phase 3 clinical trial in China for lingdolinurad (ABP-671). The first patient has been successfully enrolled and dosed.
The Phase 3 portion of this multicenter, randomized, double-blind, parallel-controlled Phase 2b/3 clinical trial plans to enroll more than 800 gout patients in China. The study will directly compare lingdolinurad with febuxostat to evaluate its efficacy and safety in patients with gout. Tophaceous gout patients will be included in this study to evaluate lingdolinurad’s potential to reduce the size or eliminate tophi. The results are expected to provide robust and reliable evidence to support future regulatory submissions for marketing approval in China.
Dr. William Dongfang Shi, Founder, Chairman and CEO of Atom Therapeutics, commented, “Lingdolinurad is being developed under a synchronized clinical development strategy in both China and the US. In addition to the ongoing Phase 3 clinical trial in China, the overseas Phase 3 program, which is primarily conducted in the US, has been reviewed by the FDA and is planned to be initiated later this year.”
